Targeting CD8+ T-cell tolerance for cancer immunotherapy

Immunotherapy

Volumn 6, Issue 7, 2014, Pages 833-852

  Jackson, Stephanie R ^a,b   Yuan, Jinyun ^a,b   Teague, Ryan M ^a,b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SAINT LOUIS UNIVERSITY CANCER CENTER   (United States)

Author keywords

adoptive cell transfer; cancer immunotherapy; cancer vaccine; CD8+ T cell checkpoint blockade; chimeric antigen receptor; lymphodepletion; tolerance

Indexed keywords

CD134 ANTIGEN; CD137 ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; PROGRAMMED DEATH 1 RECEPTOR; T LYMPHOCYTE RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL TRANSFER; HUMAN; LISTERIA MONOCYTOGENES; REVIEW; T CELL DEPLETION; TARGET CELL; TUMOR IMMUNITY; VACCINATION; ANIMAL; CELLULAR IMMUNITY; GENETIC ENGINEERING; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; PATHOLOGY; PROCEDURES;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; GENETIC ENGINEERING; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNOTHERAPY; RECEPTORS, ANTIGEN, T-CELL;

EID: 84907812369     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.51     Document Type: Review

References (145)

1. Coley WB. II. Contribution to the Knowledge of sarcoma. Ann. Surg. 14(3), 199-220 (1891
2. Mitchison NA. Studies on the immunological response to foreign tumor transplants in the mouse. I. The role of lymph node cells in conferring immunity by adoptive transfer. J. Exp. Med. 102(2), 157-177 (1955
3. Hernandez J, Aung S, Redmond WL, Sherman LA. Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of selfantigen. J. Exp. Med. 194(6), 707-717 (2001
4. Redmond WL, Sherman LA. Peripheral tolerance of CD8 T lymphocytes. Immunity 22(3), 275-284 (2005
5. Morgan DA, Ruscetti FW, Gallo R. Selective in vitro growth of T lymphocytes from normal human bone marrows. Science 193(4257), 1007-1008 (1976
6. Lotze MT, Robb RJ, Sharrow SO, Frana LW, Rosenberg SA. Systemic administration of interleukin-2 in humans. J. Biol. Response Mod. 3(5), 475-482 (1984
7. Lotze MT, Matory YL, Ettinghausen SE et al. In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J. Immunol. 135(4), 2865-2875 (1985
8. Cheever MA, Thompson JA, Peace DJ, Greenberg PD. Potential uses of interleukin 2 in cancer therapy. Immunobiology 172(3-5), 365-382 (1986
9. Lotze MT, Chang AE, Seipp CA, Simpson C, Vetto JT, Rosenberg SA. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA 256(22), 3117-3124 (1986
10. Rosenberg SA. Raising the bar: the curative potential of human cancer immunotherapy. Sci. Transl. Med. 4(127), S128 (2012
11. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity 33(2), 153-165 (2010
12. Liao W, Lin JX, Leonard WJ. Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy. Immunity 38(1), 13-25 (2013
13. Siegel JP, Sharon M, Smith PL, Leonard WJ. The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science 238(4823), 75-78 (1987
14. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T-cells. Nat. Immunol. 4(4), 330-336 (2003
15. Saadoun D, Rosenzwajg M, Joly F et al. Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N. Engl. J. Med. 365(22), 2067-2077 (2011
16. Lee PP, Yee C, Savage PA et al. Characterization of circulating T cells specific for tumor-Associated antigens in melanoma patients. Nat. Med. 5(6), 677-685 (1999
17. Rosenberg SA, Yang JC, Schwartzentruber DJ et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4(3), 321-327 (1998
18. Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594), 850-854 (2002
19. Boyman O, Kovar M, Rubinstein MP, Surh CD, Sprent J. Selective stimulation of T-cell subsets with antibody-cytokine immune complexes. Science 311(5769), 1924-1927 (2006
20. Fishman MN, Thompson JA, Pennock GK et al. Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A 0201 complex, in patients with advanced malignancies. Clin. Cancer Res. 17(24), 7765-7775 (2011
21. Levin AM, Bates DL, Ring AM et al. Exploiting a natural conformational switch to engineer an interleukin-2'superkine'. Nature 484(7395), 529-533 (2012
22. Rochman Y, Spolski R, Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat.Rev. Immunol. 9(7), 480-490 (2009
23. Teague RM, Sather BD, Sacks JA et al. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat. Med. 12(3), 335-341 (2006
24. Hinrichs CS, Spolski R, Paulos CM et al. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 111(11), 5326-5333 (2008
25. Waldmann TA. The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design. Nat. Rev. Immunol. 6(8), 595-601 (2006
26. Rubinstein MP, Kovar M, Purton JF et al. Converting IL-15 to a superagonist by binding to soluble IL-15R{alpha}. Proc. Natl Acad. Sci. USA 103(24), 9166-9171 (2006
27. Han KP, Zhu X, Liu B et al. IL-15:IL-15 receptor alpha superagonist complex: high-level co-expression in recombinant mammalian cells, purification and characterization. Cytokine 56(3), 804-810 (2011
28. Xu W, Jones M, Liu B et al. Efficacy and mechanism-ofaction of a novel superagonist interleukin-15: interleukin-15 receptor alphaSu/Fc fusion complex in syngeneic murine models of multiple myeloma. Cancer Res. 73(10), 3075-3086 (2013
29. Spolski R, Leonard WJ. Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu. Rev. Immunol. 26, 57-79 (2008
30. Zeng R, Spolski R, Finkelstein SE et al. Synergy of IL-21 and IL-15 in regulating CD8+ T-cell expansion and function. J. Exp. Med. 201(1), 139-148 (2005
31. Clough LE, Wang CJ, Schmidt EM et al. Release from regulatory T-cell-mediated suppression During the onset of tissue-specific autoimmunity is associated with elevated IL-21. J. Immunol. 180(8), 5393-5401 (2008
32. Li Y, Yee C. IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood 111(1), 229-235 (2008
33. Peluso I, Fantini MC, Fina D et al. IL-21 counteracts the regulatory T-cell-mediated suppression of human CD4+T lymphocytes. J. Immunol. 178(2), 732-739 (2007
34. Jung G, Ledbetter JA, Muller-Eberhard HJ. Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates. Proc. Natl Acad. Sci. USA 84(13), 4611-4615 (1987
35. Suntharalingam G, Perry MR, Ward S et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355(10), 1018-1028 (2006
36. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12(4), 252-264 (2012
37. Stromnes IM, Schmitt TM, Chapuis AG, Hingorani SR, Greenberg PD. Re-Adapting T cells for cancer therapy: from mouse models to clinical trials. Immunol. Rev. 257(1), 145-164 (2014
38. Cheadle EJ, Gornall H, Baldan V, Hanson V, Hawkins RE, Gilham DE. CAR T-cells: driving the road from the laboratory to the clinic. Immunol. Rev. 257(1), 91-106 (2014
39. Mallett S, Fossum S, Barclay AN. Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes-A molecule related to nerve growth factor receptor. Embo. J. 9(4), 1063-1068 (1990
40. Godfrey WR, Fagnoni FF, Harara MA, Buck D, Engleman EG. Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J. Exp. Med. 180(2), 757-762 (1994
41. Watts TH. TNF/TNFR family members in costimulation of T-cell responses. Annu. Rev. Immunol. 23, 23-68 (2005
42. Gramaglia I, Weinberg AD, Lemon M, Croft M. Ox-40 ligand: a potent costimulatory molecule for sustaining primary CD4 T-cell responses. J. Immunol. 161(12), 6510-6517 (1998
43. Rogers PR, Song J, Gramaglia I, Killeen N, Croft M. OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-Term survival of CD4 T cells. Immunity 15(3), 445-455 (2001
44. Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res. 68(13), 5206-5215 (2008
45. Vu MD, Xiao X, Gao W et al. OX40 costimulation turns off Foxp3+ Tregs. Blood 110(7), 2501-2510 (2007
46. Vetto JT, Lum S, Morris A et al. Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am. J. Surg. 174(3), 258-265 (1997
47. Curti BD, Kovacsovics-Bankowski M, Morris N et al. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res. 73(24), 7189-7198 (2013
48. Hernandez-Chacon JA, Li Y, Wu RC et al. Costimulation through the CD137/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activationinduced cell death and enhances antitumor effector function. J. Immunother. 34(3), 236-250 (2011
49. Melero I, Shuford WW, Newby SA et al. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 3(6), 682-685 (1997
50. Shuford WW, Klussman K, Tritchler DD et al. 4-1BB costimulatory signals preferentially induce CD8+ T-cell proliferation and lead to the amplification in vivo of cytotoxic T-cell responses. J. Exp. Med. 186(1), 47-55 (1997
51. Wilcox RA, Flies DB, Zhu G et al. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J. Clin. Invest. 109(5), 651-659 (2002
52. Molckovsky A, Siu LL. First-in-class, first-in-human Phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J. Hematol. Oncol. 1, 20 (2008
53. Sotomayor EM, Borrello I, Tubb E et al. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40. Nat. Med. 5(7), 780-787 (1999
54. Diehl L, Den Boer AT, Schoenberger SP et al. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments antitumor vaccine efficacy. Nat. Med. 5(7), 774-779 (1999
55. French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 5(5), 548-553 (1999
56. Zhang L, Chen X, Liu X et al. CD40 ligation reverses T-cell tolerance in acute myeloid leukemia. J. Clin. Invest. 123(5), 1999-2010 (2013
57. Bensinger W, Maziarz RT, Jagannath S et al. A Phase 1 study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. Br. J. Haematol. 159(1), 58-66 (2012
58. Byrd JC, Kipps TJ, Flinn IW et al. Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia. Leuk. Lymphoma 53(11), 2136-2142 (2012
59. Furman RR, Forero-Torres A, Shustov A, Drachman JG. A Phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leuk. Lymphoma 51(2), 228-235 (2010
60. Hussein M, Berenson JR, Niesvizky R et al. A Phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma. Haematologica 95(5), 845-848 (2010
61. Vonderheide RH, Flaherty KT, Khalil M et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J. Clin. Oncol. 25(7), 876-883 (2007
62. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 392(6673), 245-252 (1998
63. Hawiger D, Inaba K, Dorsett Y et al. Dendritic cells induce peripheral T-cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194(6), 769-779 (2001
64. Banchereau J, Thompson-Snipes L, Zurawski S et al. The differential production of cytokines by human Langerhans cells and dermal CD14(+) DCs controls CTL priming. Blood 119(24), 5742-5749 (2012
65. Chen L, Ashe S, Brady WA et al. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 71(7), 1093-1102 (1992
66. Ueno H, Schmitt N, Klechevsky E et al. Harnessing human Dendritic cell subsets for medicine. Immunol. Rev. 234(1), 199-212 (2010
67. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer 12(4), 265-277 (2012
68. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010
69. Bonifaz LC, Bonnyay DP, Charalambous A et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T-cell vaccination. J. Exp. Med. 199(6), 815-824 (2004
70. Ribas A, Comin-Anduix B, Chmielowski B et al. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin. Cancer Res. 15(19), 6267-6276 (2009
71. Bahjat KS, Liu W, Lemmens EE et al. Cytosolic entry controls CD8+-T-cell potency during bacterial infection. Infect. Immun. 74(11), 6387-6397 (2006
72. Souders NC, Sewell DA, Pan ZK et al. Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer. Cancer Immun. 7, 2 (2007
73. Na SY, Hermann A, Sanchez-Ruiz M, Storch A, Deckert M, Hunig T. Oligodendrocytes enforce immune tolerance of the uninfected brain by purging the peripheral repertoire of autoreactive CD8+ T cells. Immunity 37(1), 134-146 (2012
74. Shahabi V, Reyes-Reyes M, Wallecha A, Rivera S, Paterson Y, Maciag P. Development of a Listeria monocytogenes based vaccine against prostate cancer. Cancer Immunol. Immunother. 57(9), 1301-1313 (2008
75. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T-cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J. Immunol. 167(11), 6471-6479 (2001
76. Maciag PC, Radulovic S, Rothman J. The first clinical use of a live-Attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 27(30), 3975-3983 (2009
77. Le DT, Brockstedt DG, Nir-Paz R et al. A live-Attenuated Listeria vaccine (ANZ-100) and a live-Attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin. Cancer Res. 18(3), 858-868 (2012
78. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 8(4), 299-308 (2008
79. Schmitt TM, Ragnarsson GB, Greenberg PD. T-cell receptor gene therapy for cancer. Hum. Gene Ther. 20(11), 1240-1248 (2009
80. Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796), 126-129 (2006
81. Schmitt TM, Aggen DH, Stromnes IM et al. Enhancedaffinity murine T-cell receptors for tumor/self-Antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood 122(3), 348-356 (2013
82. Robbins PF, Morgan RA, Feldman SA et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J. Clin. Oncol. 29(7), 917-924 (2011
83. Morgan RA, Chinnasamy N, Abate-Daga D et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. 36(2), 133-151 (2013
84. Linette GP, Stadtmauer EA, Maus MV et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122(6), 863-871 (2013
85. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T-cell response. Nat. Rev. Immunol. 12(4), 269-281 (2012
86. Song DG, Ye Q, Carpenito C et al. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T-cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res. 71(13), 4617-4627 (2011
87. Grupp SA, Kalos M, Barrett D et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N. Engl. J. Med. 368(16), 1509-1518 (2013
88. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr. Opin. Immunol. 21(2), 215-223 (2009
89. ClinicalTrials.Gov: www.ClinicalTrials.gov
90. Chmielewski M, Hombach AA, Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol. Rev. 257(1), 83-90 (2014
91. Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 71(17), 5697-5706 (2011
92. Pegram HJ, Lee JC, Hayman EG et al. Tumor-Targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 119(18), 4133-4141 (2012
93. Chmielewski M, Abken H. CAR T cells transform to trucks: chimeric antigen receptor-redirected T cells engineered to deliver inducible IL-12 modulate the tumour stroma to combat cancer. Cancer Immunol. Immunother. 61(8), 1269-1277 (2012
94. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T-cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18(4), 843-851 (2010
95. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a Phase I clinical trial. Mol. Ther. 18(4), 666-668 (2010
96. Budde LE, Berger C, Lin Y et al. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T-cell adoptive immunotherapy for lymphoma. PLoS ONE 8(12), e82742 (2013
97. Goldrath AW, Bogatzki LY, Bevan MJ. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J. Exp. Med. 192(4), 557-564 (2000
98. Cho BK, Rao VP, Ge Q, Eisen HN, Chen J. Homeostasisstimulated proliferation Drives naive T cells to differentiate directly into memory T cells. J. Exp. Med. 192(4), 549-556 (2000
99. Schietinger A, Delrow JJ, Basom RS, Blattman JN, Greenberg PD. Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 335(6069), 723-727 (2012
100. Eberlein TJ, Rosenstein M, Rosenberg SA. Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J. Exp. Med. 156(2), 385-397 (1982
101. North RJ. Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T-cells. J. Exp. Med. 155(4), 1063-1074 (1982
102. Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23(10), 2346-2357 (2005
103. Gattinoni L, Finkelstein SE, Klebanoff CA et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+T cells. J. Exp. Med. 202(7), 907-912 (2005
104. Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17(13), 4550-4557 (2011
105. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9), 942-949 (2004
106. Schubert LA, Jeffery E, Zhang Y, Ramsdell F, Ziegler SF. Scurfin (FOXP3) acts as a repressor of transcription and regulates T-cell activation. J. Biol. Chem. 276(40), 37672-37679 (2001
107. Savage PA, Malchow S, Leventhal DS. Basic principles of tumor-Associated regulatory T-cell biology. Trends Immunol. 34(1), 33-40 (2013
108. Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccinemediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. 115(12), 3623-3633 (2005
109. Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann. NY Acad. Sci. 1174, 99-106 (2009
110. Jacobs JF, Punt CJ, Lesterhuis WJ et al. Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a Phase I/II study in metastatic melanoma patients. Clin. Cancer Res. 16(20), 5067-5078 (2010
111. Hodi FS, Butler M, Oble DA et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyteassociated antigen 4 in previously vaccinated cancer patients. Proc. Natl Acad. Sci. USA 105(8), 3005-3010 (2008
112. Simpson TR, Li F, Montalvo-Ortiz W et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. (2013
113. Almand B, Clark JI, Nikitina E et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 166(1), 678-689 (2001
114. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity. Cancer Immunol. Immunother. 59(10), 1593-1600 (2010
115. Nagaraj S, Schrum AG, Cho HI, Celis E, Gabrilovich DI. Mechanism of T-cell tolerance induced by myeloid-derived suppressor cells. J. Immunol. 184(6), 3106-3116 (2010
116. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett- Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicincyclophosphamide chemotherapy. Cancer Immunol. Immunother. 58(1), 49-59 (2009
117. Najjar YG, Finke JH. Clinical perspectives on targeting of myeloid derived suppressor cells in the treatment of cancer. Front. Oncol. 3, 49 (2013
118. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3(7), 611-618 (2002
119. Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270(5238), 985-988 (1995
120. Lee KM, Chuang E, Griffin M et al. Molecular basis of T-cell inactivation by CTLA-4. Science 282(5397), 2263-2266 (1998
121. Guntermann C, Alexander DR. CTLA-4 suppresses proximal TCR signaling in resting human CD4(+) T cells by inhibiting ZAP-70 Tyr(319) phosphorylation: a potential role for tyrosine phosphatases. J. Immunol. 168(9), 4420-4429 (2002
122. Qureshi OS, Zheng Y, Nakamura K et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332(6029), 600-603 (2011
123. Hodi FS, O'day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711-723 (2010
124. Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyteassociated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J. Exp. Med. 192(2), 295-302 (2000
125. Takahashi T, Tagami T, Yamazaki S et al. Immunologic selftolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-Associated antigen 4. J. Exp. Med. 192(2), 303-310 (2000
126. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. Nat. Immunol. 8(3), 239-245 (2007
127. Barber DL, Wherry EJ, Masopust D et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077), 682-687 (2006
128. Berrien-Elliott MM, Jackson SR, Meyer JM et al. Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+T-cell tolerance. Cancer Res. 73(2), 605-616 (2013
129. Zhang L, Gajewski TF, Kline J. PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model. Blood 114(8), 1545-1552 (2009
130. Patsoukis N, Brown J, Petkova V, Liu F, Li L, Boussiotis VA. Selective effects of PD-1 on Akt and Ras pathways regulate molecular components of the cell cycle and inhibit T-cell proliferation. Sci. Signal 5(230), ra46 (2012
131. Dong H, Strome SE, Salomao DR et al. Tumor-Associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8(8), 793-800 (2002
132. Brahmer JR, Tykodi SS, Chow LQ et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366(26), 2455-2465 (2012
133. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012
134. Hamid O, Robert C, Daud A et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 369(2), 134-144 (2013
135. Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J. Clin. Oncol. 30(21), 2691-2697 (2012
136. Gangadhar TC, Vonderheide RH. Mitigating the toxic effects of anticancer immunotherapy. Nat. Rev. Clin. Oncol. 11(2), 91-99 (2014
137. Huang CT, Workman CJ, Flies D et al. Role of LAG-3 in regulatory T cells. Immunity 21(4), 503-513 (2004
138. Sabatos CA, Chakravarti S, Cha E et al. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat. Immunol. 4(11), 1102-1110 (2003
139. Sanchez-Fueyo A, Tian J, Picarella D et al. Tim-3 inhibits T helper type 1-mediated auto- And alloimmune responses and promotes immunological tolerance. Nat. Immunol. 4(11), 1093-1101 (2003
140. Teague RM, Kline J. Immune evasion in acute myeloid leukemia: current concepts and future directions. J. Immunother. Cancer 1(13), (2013
141. Riley JL. Combination checkpoint blockade-Taking melanoma immunotherapy to the next level. N. Engl. J. Med. 369(2), 187-189 (2013
142. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA 107(9), 4275-4280 (2010
143. Grosso JF, Goldberg MV, Getnet D et al. Functionally distinct LAG-3 and PD-1 subsets on activated and chronically stimulated CD8 T cells. J. Immunol. 182(11), 6659-6669 (2009
144. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T-cell exhaustion and restore antitumor immunity. J. Exp. Med. 207(10), 2187-2194 (2010
145. Wolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 369(2), 122-133 (2013